reports
Axogen Announces Appointment of Rick Ditto as Vice President, Global H...
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of...
Axogen, Inc. To Host Analyst & Investor Day on March 4th
Axogen, Inc. To Host Analyst & Investor Day on March 4th ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern. Featured speakers will include Chief Executive Officer - Michael Dale, Chief Financial Officer - Nir Naor, and other senior members of the leadership team. During the event, the Axogen team will offer an overview of the business, strategic initiatives and g...
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Resul...
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fourth ...
Axogen, Inc. to report 2024 fourth quarter and full year financial res...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating i...
Axogen Announces Appointment of Jesse Bishop as Vice President of Regu...
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulator...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WHR WHIRLPOOL CORPORATION
SLAB SILICON LABORATORIES INC.
LAKE LAKELAND INDUSTRIES INC.
GTE GRAN TIERRA ENERGY
DXPE DXP ENTERPRISES INC.
COG CABOT OIL & GAS CORPORATION
AXGN AXOGEN INC.
ALLT ALLOT LTD
MEG. MEG ENERGY CORP.
PARR PAR PACIFIC HOLDINGS INC
VFC V.F. CORPORATION
CDZI CADIZ INC.
IRTC IRHYTHM TECHNOLOGIES INC.
DK DELEK US HOLDINGS INC
SWTX SPRINGWORKS THERAPEUTICS
PGNY PROGYNY
CRMD CORMEDIX INC.
LPI LAREDO PETROLEUM INC.
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
OVV OVINTIV INC
PTLO PORTILLOS INC
CIVI CIVITAS RESOURCES INC
ARHS ARHAUS INC
OPFI OPPFI INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
SN SHARKNINJA INC
ARPL ARLA PLAST AB
Axogen Announces New VP of Operations and Inducement Grant Under Nasda...
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Craig Swandal, experienced medical device manufacturing executive, joins leadership team ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations. Mr. Swandal will report to Michael Dale, President, and Chief Executive Officer, and will be responsible for manufacturing, sup...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Fu...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by s...
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides ...
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% i...
Axogen, Inc. to report third quarter 2024 financial results and host c...
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the ...
Axogen Completes Submission of Biologics License Application to U.S. F...
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. “I am proud of the significant progress our team has made towards the regulatory transition o...
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing R...
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced today that it has granted an equity inducement award on September 3, 2024, to a new non-executive employee under the terms of the Axogen Inc.’s Inducement Equity Incentive Plan. The award was approved by the Compensation Committee of Axogen’s Board of Directors in accordance with NASDAQ Listing Rule...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLDN WILLDAN GROUP
VIRC VIRCO MANUFACTURING CORP.
TBBK THE BANCORP
PSIX POWER SOLUTIONS INTERNATIONAL INC.
NWPX NORTHWEST PIPE CO.
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS INC.
BFIN BANKFINANCIAL
AXGN AXOGEN INC.
ASPN ASPEN AEROGELS
MG/CN MAGNA INTERNATIONAL INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
GLOB GLOBANT SA
NGS NATURAL GAS SERVICES GROUP INC.
SGMS SCIENTIFIC GAMES CORPORATION
HRB H&R BLOCK INC.
MHH MASTECH DIGITAL
KINS KINGSTONE COS. INC.
FEIM FREQUENCY ELECTRONICS INC.
SIGA SIGA TECHNOLOGIES INC.
SNFCA SECURITY NATIONAL FINANCIAL CORP. CL A
PSNL PERSONALIS
VHI VALHI INC.
KLXE KLX ENERGY SERVICES
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
CLBT CELLEBRITE DI LTD
CINT CI&T INC
RKLB ROCKET LAB USA INC
PGRU PROPERTYGURU GROUP LTD
COHR COHERENT CORP
REAX ADL VENTURES INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
FIHL FIDELIS INSURANCE HOLDINGS LIMITED
LTH LIFE TIME GROUP HLDGS INC
ANG ANGLOGOLD ASHANTI LIMITED
HG HAMILTON INSURANCE GROUP LTD.
AKA AKA BRANDS HOLDING CORP
UBXG U BX TECHNOLOGY LTD
TEM TEMPUS AI INC
BVS BAYVIEW CAPITAL TRUST I PFD 9.76%
Axogen, Inc. Announces New Leadership Appointments
Axogen, Inc. Announces New Leadership Appointments The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective August 9, 2024 ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief execut...
Axogen, Inc. Reports Second Quarter 2024 Financial Results
Axogen, Inc. Reports Second Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased t...
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host ...
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conferen...
Company Reports Inducement Grants to Non-Executive New Employee Under ...
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. In connection with the commencement of employment on June 17, 2024, and as a material inducement of employment, an award was made under the Co...
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™ ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distribute...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leader...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold ind...
Axogen Inc. Initiates Rolling Submission of Biologics License Applicat...
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024. “Today’s milestone represents a signific...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.